

Demand Recovery Will Be Gradual; Maintain BUY

Est. Vs. Actual for Q4FY24: Revenue – **INLINE**; EBITDA – **MISS**; PAT – **INLINE**

Changes in Estimates post Q4FY24

FY25E/FY26E: Revenue: -2%/-4%; EBITDA: -3%/-5%; PAT: -3%/-6%

Recommendation Rationale

- Volume growth to recover gradually:** The management reiterated that overall volume growth is likely to recover gradually, led by a normal monsoon outlook and improving macroeconomic indicators. However, EBITDA margins are likely to remain at current levels as it continues to step up investments in A&P.
- Market share gains through premiumisation and operational efficiency:** HUL's overall Q4FY24 results were in line with our estimates with no meaningful recovery on the demand front. Home care (up 1% YoY) and BPC (down 2% YoY) remain challenging and were impacted on account of price cuts in fabric wash and skin care portfolio. F&R grew 4% (flat volume growth), led by Health Drinks, Foods and coffee. Gross margins improved 350bps YoY to 51.3% on account of improved efficiencies and improving product mix (~25% of portfolio is premium). However, EBITDA margins declined 19bps YoY to 23.1% on account of termination of GSK commission business (60bps impact), increase in royalty payment, and increase in ad-spends (up 23% YoY).

Sector Outlook: Cautious

Company Outlook & Guidance: We maintain a **BUY** rating on the stock **as we continue to remain positive on the company's long-term prospects**. However, we cut our FY25/26 EPS to account for near-term volume pressure as we expect demand revival to be gradual.

Current Valuation: 51x Mar'26 EPS (Earlier Valuation: 56x Dec'25 EPS).

Current TP: Rs 2,500/share (Earlier TP: Rs 2,850/share).

Recommendation With an 11% upside from the CMP, we maintain our long-term **BUY** rating on the stock.

Financial Performance: HUL reported flat revenue growth (2% volume growth) to Rs 14,693 Cr, which was in line with our/cons estimates. This was on account of a subdued demand environment. Furthermore, price cuts in the Home Care and Skin Care segments impacted the overall revenue growth. Premium portfolio (~25% of the portfolio) continues to remain strong and urban business continues to grow faster than rural. The management reiterated that it has gained market share in over 60% of the portfolio across categories. The company's gross margins improved 350bps YoY to 51.3%; however, EBITDA margin expansion declined 19bps YoY to 23.1% owing to higher ad spends, royalty payments, and termination of GSK commission business. Adj. PAT stood at Rs 2,396 Cr, down 3% YoY.

Outlook: Management is cautiously optimistic about demand as the recovery in the country will be gradual, supported by a better monsoon and better macroeconomic indicators. In addition, management emphasised that price growth could remain negative in the low single digits in the near term if commodity prices remain at current levels. However, EBITDA margins are expected to remain at current levels due to higher advertising spend and the termination of GSK's commission business. In the longer term, however, HUL's growth prospects remain good as management focuses on the following: (1) Promoting a diversified portfolio and spreading the price-value matrix to drive premiumization; (2) Continued focus on efficiency improvement – nano factories, automation and scaling Shikar to 1.3 million outlets to drive overall cost saving initiatives; (3) Market development initiatives to gain market share across the portfolio; and (4) Strong execution capabilities (demonstrating the strength of the company with its diverse product portfolio and financial strength in this volatile and challenging environment).

Valuation & Recommendation: We expect HUL's Sales/EBITDA/PAT to grow at 6%/6%/5% CAGR over FY23-26E. We maintain our **BUY** stance with a revised TP of Rs 2,500/share, with an upside of 11% from the CMP.

Key Financials (Standalone)

(Rs Cr)	Q4FY24	QoQ (%)	YoY (%)	Axis Est.	Variance (%)
Net Sales	14,693	(1.6)	0.4	14,776	(0.6)
EBITDA	3,435	(3.0)	(1.0)	3,481	(1.3)
EBITDA Margin (%)	23.1	-19 bps	-19 bps	23.2	-6 bps
Net Profit	2,396	(5.7)	(3.0)	2,407	(0.5)
EPS (Rs)	10	(5.7)	(3.0)	10	(0.5)

Source: Company, Axis Research

(CMP as of 24 th April 2024)	
CMP (Rs)	2260
Upside /Downside (%)	11%
High/Low (Rs)	2768/2170
Market cap (Cr)	5,30,807
Avg. daily vol. (6m) Shrs'000.	1860
No. of shares (Cr)	235

Shareholding (%)

	Sep-23	Dec-23	Mar-24
Promoter	61.9	61.9	61.9
FII	13.9	13.7	12.7
MFs / UTI	4.8	4.8	5.0
Banks / FII	0.1	0.1	0.1
Others	19.3	19.6	20.4

Financial & Valuations

Y/E Mar (Rs Cr)	FY24E	FY25E	FY26E
Net Sales	59,579	63,821	68,365
EBITDA	14,190	15,218	16,320
Net Profit	10,114	10,854	11,578
EPS, Rs	43.0	46.2	49.3
PER, x	55.1	51.8	48.5
EV/EBITDA, x	39.1	36.4	33.8
ROE (%)	20.2	21.3	22.4

Change in Estimates (%)

Y/E Mar	FY25E	FY26E
Sales	(2)	(4)
EBITDA	(3)	(5)
PAT	(3)	(6)


ESG disclosure Score**

Environmental Disclosure	18.30
Social Disclosure Score	24.51
Governance Disclosure Score	86.09
Total ESG Disclosure Score	43.02
Sector Average	44.87

Source: Bloomberg, Scale: 0.1-100

**Note: This score measures the amount of ESG data a company reports publicly and does not measure the company's performance on any data point. All scores are based on 2022 disclosures

Relative performance



Source: Ace Equity, Axis Securities

Preeyam Tolia

Research Analyst

email: preeyam.tolia@axissecurities.in

Suhaneet Shome

Research Associate

email: suhaneet.shome@axissecurities.in

Key Highlights & Concall Takeaways

- Home care** – Home Care grew by a marginal 1% with mid-single-digit UVG in Q4. However, on a 2-year CAGR basis, it delivered double-digit volume growth. Both fabric wash and Household care grew in mid-single digits, led by a strong performance in the premium portfolio and Vim Liquid, which continues to maintain its No. 1 position. However, on a YoY basis, both categories witnessed a decline in price growth due to price actions implemented during the year.
- Beauty & Personal Care** – The Beauty & Wellbeing segment witnessed strong growth of 4%, led by outperformance in the premium portfolio. However, overall, the Beauty and Personal Care segment had a USG of -2% with flat volumes. The Hair and Care portfolio delivered volume-driven high-single-digit growth, led by strong performance in Dove and Tresemme. Skin Care and Colour Cosmetics grew in low-single digits, along with underperformance in the mass portfolio segment. However, Premium Skin continued to deliver its strong double-digit growth trajectory, led by innovations in new demand spaces and formats. The Skin Cleansing business declined due to the impact of price cuts coupled with a drop in volumes in the mass and popular segments. Body wash continues to perform well. On the other hand, Oral Care witnessed double-digit broad-based growth driven by pricing. Additionally, a range of innovations were introduced under Lakme Cosmetics, Sun-care products under Glow and Lovely, Ponds, and Lakme skin and sensitive skin cleansing range by Dove.
- Foods & Refreshment** – Foods & Refreshment revenue grew by 4%, with flat volume growth. The company further strengthened its value and volume market leadership in the Tea segment. Furthermore, the category continued to witness consumers downgrading loose tea in favour of branded ones. Coffee grew in double digits, driven by pricing. Functional Nutritional Drinks (Horlicks & Boost) delivered high-single-digit growth driven by the Plus range and witnessed strong penetration gains during FY24 on the back of sustained market development actions. Foods grew in mid-single digits, led by strong performance in Soups and Food solutions. Mayonnaise and Peanut Butter continue to gain traction with consumers. The Ice Creams category performed well, growing in double digits led by volume. Several innovations under this category, including Cadbury Crackle Feast, American Nuts, and Mango Duet, were launched ahead of the upcoming summer season.

Key Risks to our Estimates and TP

- Prolonged recovery in rural, raw material inflation, and increase in competitive intensity.

Change in Estimates

	Old Est.		Revised Est.		% Revision	
	FY25E	FY26E	FY25E	FY26E	FY25E	FY26E
Revenue	65,409	71,564	63,821	68,365	(2)	(4)
EBITDA	15,647	17,249	15,218	16,320	(3)	(5)
PAT	11,144	12,324	10,854	11,578	(3)	(6)
EPS	47.4	52.4	46.2	49.3	(3)	(6)

Source: Company, Axis Securities

ResultsReview

(Rs Cr)	Q4FY23	Q3FY24	Axis Sec Est	Q4FY24	YoY growth %	QoQ growth %	Axis Sec Var (%)
Volume growth (% yoy)	4.0	2.0	3.0	2.0			
Net Sales	14,638	14,928	14,776	14,693	0.4	(1.6)	(0.6)
Gross Profits	6,999	7,561	7,671	7,542	7.8	(0.3)	(1.7)
Gross Margin (%)	47.8	50.6	51.9	51.3	352 bps	68 bps	-59 bps
Staff costs	683	649	690	774	13.3	19.3	12.2
Ad spends	1,290	1,593	1,716	1,586	22.9	(0.4)	(7.6)
Other operating expenses	1,810	2,039	2,027	1,911	5.6	(6.3)	(5.7)
EBITDA	3,471	3,540	3,481	3,435	(1.0)	(3.0)	(1.3)
EBITDA Margin (%)	23.3	23.3	23.2	23.1	-19 bps	-19 bps	-6 bps
Depreciation	262	282	296	289	7.6	2.5	(2.4)
EBIT	3,209	3,258	3,185	3,146	1.5	(3.4)	(1.2)
Other Income	160	285	176	220	78.1	(22.8)	25.0
Interest Expenses	24	81	81	102	237.5	25.9	25.3
PBT	3,425	3,432	3,279	3,247	(5.2)	(5.4)	(1.0)
Tax rate (%)	25.5	26.6	26.6	25.9	41 bps	-70 bps	-70 bps
PAT	2,471	2,541	2,407	2,396	(3.0)	(5.7)	(0.5)
EPS (Rs.)	10.5	10.8	10.2	10.2	(3.0)	(5.7)	(0.5)

Source: Company, Axis Securities

Segmental Performance

Revenue (Rs Cr)	Q4FY23	Q3FY24	Q4FY24	YoY %	QoQ %
Home Care	5,638	5,448	5,715	1.4	4.9
Personal Care	5,188	5,705	5,050	(2.7)	(11.5)
Foods & Refreshment	3,794	3,733	3,911	3.1	4.8
Others	273	302	181	(33.7)	(40.1)
Total segment revenue	14,893	15,188	14,857	(0.2)	(2.2)

Segment results (Rs Cr)

Home Care	1,056	966	1,081	2.4	11.9
Personal Care	1,353	1,461	1,288	(4.8)	(11.8)
Foods & Refreshments	679	711	739	8.8	3.9
Others	121	120	38	(68.6)	(68.3)
Total segment results	3,209	3,258	3,146	(2.0)	(3.4)

Segment margins %

Home Care	18.7	17.7	18.9	19 bps	118 bps
Personal Care	26.1	25.6	25.5	-57 bps	-10 bps
Foods & Refreshment	17.9	19.0	18.9	100 bps	-15 bps
Others	44.3	39.7	21.0	-2333 bps	-1874 bps
Total segment Margins	21.5	21.5	21.2	-37 bps	-28 bps

Source: Company, Axis Securities

Financials (Standalone)

Profit & Loss

(Rs Cr)

Y/E Mar, Rs Cr	FY23	FY24	FY25E	FY26E
Net sales	58,154	59,579	63,821	68,365
Growth, %	15.5	2.5	7.1	7.1
Other operating income	990	890	899	908
Total income	59,144	60,469	64,720	69,273
Raw material expenses	(31,144)	(29,327)	(31,087)	(33,263)
Employee expenses	(2,665)	(2,782)	(3,060)	(3,274)
Other Operating expenses	(11,703)	(14,170)	(15,355)	(16,416)
EBITDA (Core)	13,632	14,190	15,218	16,320
Growth, %	9.0	4.1	7.2	7.2
Margin, %	23.4	23.8	23.8	23.9
Depreciation	(1,030)	(1,097)	(1,215)	(1,334)
EBIT	12,602	13,093	14,002	14,986
Growth, %	10	4	7	7
Margin, %	22	22	22	22
Interest paid	(101)	(302)	(317)	(333)
Other Income	640	973	983	993
Non-recurring Items	(62)	(89)	-	-
Pre-tax profit	13,079	13,675	14,668	15,646
Tax provided	(3,117)	(3,561)	(3,814)	(4,068)
Profit after tax	9,962	10,114	10,854	11,578
Growth, %	13.2	1.8	6.4	6.7
Net Profit (adjusted)	9,962	10,114	10,854	11,578
Unadj. shares (Cr)	235	235	235	235
Wtdavg shares (Cr)	235	235	235	235

Source: Company, Axis Securities

Balance Sheet

(Rs Cr)

As of 31st Mar, Rs Cr	FY23	FY24E	FY25E	FY26E
Cash & bank	4,422	4,882	5,719	6,904
Marketable securities at cost	2,811	2,811	2,811	2,811
Debtors	2,735	2,802	3,002	3,215
Inventory	4,031	3,918	4,196	4,495
Other current assets	2,015	2,015	2,015	2,015
Total current assets	16,014	16,427	17,743	19,441
Investments	2	2	2	2
Gross fixed assets	55,736	56,936	58,136	59,336
Less: Depreciation	(4,331)	(5,428)	(6,643)	(7,977)
Add: Capital WIP	1,020	1,020	1,020	1,020
Net fixed assets	52,425	52,528	52,513	52,379
Non-current assets	1,288	1,288	1,288	1,288
Total assets	71,825	72,341	73,642	75,206
Current liabilities	11,334	11,573	12,286	13,049
Provisions	1,335	1,368	1,465	1,569
Total current liabilities	12,669	12,941	13,751	14,619
Non-current liabilities	8,935	8,935	8,935	8,935
Total liabilities	21,604	21,876	22,686	23,554
Paid-up capital	235	235	235	235
Reserves & surplus	49,986	50,230	50,721	51,417
Shareholders' equity	50,221	50,465	50,956	51,652
Total equity & liabilities	71,825	72,341	73,642	75,206

Source: Company, Axis Securities

Cash Flow

(Rs Cr)

Y/E Mar, Rs Cr	FY23	FY24E	FY25E	FY26E
Pre-tax profit	13,079	13,675	14,668	15,646
Depreciation	1,030	1,097	1,215	1,334
Chg in working capital	(679)	319	332	355
Total tax paid	(2,933)	(3,561)	(3,814)	(4,068)
Other operating activities	-	-	-	-
Cash flow from operating activities	10,497	11,530	12,401	13,267
Capital expenditure	(1,520)	(1,200)	(1,200)	(1,200)
Chg in marketable securities	699	-	-	-
Other investing activities	0	0	-	-
Cash flow from investing activities	(1,192)	(1,200)	(1,200)	(1,200)
Free cash flow	9,305	10,330	11,201	12,067
Equity raised/(repaid)	(29)	-	-	-
Dividend (incl. tax)	(9,163)	(9,870)	(10,364)	(10,882)
Other financing activities	-	-	-	-
Cash flow from financing activities	(9,192)	(9,870)	(10,364)	(10,882)
Net chg in cash	113	460	838	1,185
Opening cash balance	3,618	4,422	4,882	5,719
Closing cash balance	4,422	4,882	5,719	6,904

Source: Company, Axis Securities


Ratio Analysis

(%)

Y/E Mar, Rs Cr	FY23	FY24E	FY25E	FY26E
Per Share data				
EPS (INR)	42.4	43.0	46.2	49.3
Growth, %	13.2	1.8	6.4	6.7
Book NAV/share (INR)	213.7	214.7	216.8	219.8
FDEPS (INR)	42.7	43.4	46.2	49.3
CEPS (INR)	47.3	48.5	51.4	54.9
CFPS (INR)	41.2	44.9	48.6	52.2
DPS (INR)	39.0	42.0	44.1	46.3
Return ratios				
Return on assets (%)	14.2	14.4	15.3	16.0
Return on equity (%)	20.0	20.2	21.3	22.4
Return on capital employed (%)	16.8	17.2	18.3	19.3
Turnover ratios				
Asset turnover (x)	1.2	1.2	1.3	1.4
Sales/Total assets (x)	0.8	0.8	0.9	0.9
Sales/Net FA (x)	1.1	1.1	1.2	1.3
Working capital/Sales (x)	(0.0)	(0.0)	(0.0)	(0.0)
Receivable days	17.2	17.2	17.2	17.2
Inventory days	25.3	24.0	24.0	24.0
Payable days	75.3	75.9	76.0	76.1
Working capital days	(16.0)	(17.4)	(17.6)	(17.7)
Liquidity ratios				
Current ratio (x)	1.4	1.4	1.4	1.5
Quick ratio (x)	1.1	1.1	1.1	1.1
Interest cover (x)	124.8	43.4	44.2	45.0
Net debt/Equity (%)	(8.8)	(9.7)	(11.2)	(13.4)
Valuation				
PER (x)	56.1	55.1	51.8	48.5
PEG (x) - y-o-y growth	4.2	30.8	8.1	7.3
Price/Book (x)	11.2	11.1	11.0	10.9
EV/Net sales (x)	9.5	9.3	8.7	8.1
EV/EBITDA (x)	40.7	39.1	36.4	33.8
EV/EBIT (x)	44.0	42.3	39.5	36.8

Source: Company, Axis Securities

Hindustan Unilever Price Chart and Recommendation History



Date	Reco	TP	Research
21-Jan-22	BUY	2,700	Result Update
27-Apr-22	BUY	2,450	Result Update
20-Jul-22	BUY	2,810	Result Update
25-Oct-22	BUY	2,850	Result Update
20-Jan-23	BUY	3,000	Result Update
28-Apr-23	BUY	2,800	Result Update
21-Jul-23	BUY	2,960	Result Update
20-Oct-23	BUY	2,900	Result Update
20-Jan-24	BUY	2,850	Result Update
25-Apr-24	BUY	2,500	Result Update

Source: Axis Securities

About the analyst

Analyst: Preeyam Tolia

Contact Details: preeyam.tolia@axissecurities.in

Sector: FMCG & Retail

Analyst Bio: Preeyam Tolia is MBA Finance and CFA Level 1 and part of the Axis Securities Research Team.

About the analyst

Analyst: Suhane Shome

Contact Details: suhane.shome@axissecurities.in

Sector: FMCG & Retail

Analyst Bio: Suhane Shome is MBA and part of the Axis Securities Research Team..

Disclosures:

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

1. Axis Securities Ltd. (ASL) is a SEBI Registered Research Analyst having registration no. INH000000297. ASL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. ASL is a subsidiary company of Axis Bank Ltd. Axis Bank Ltd. is a listed public company and one of India's largest private sector bank and has its various subsidiaries engaged in businesses of Asset management, NBFC, Merchant Banking, Trusteeship, Venture Capital, Stock Broking, the details in respect of which are available on www.axisbank.com.
2. ASL is registered with the Securities & Exchange Board of India (SEBI) for its stock broking & Depository participant business activities and with the Association of Mutual Funds of India (AMFI) for distribution of financial products and also registered with IRDA as a corporate agent for insurance business activity.
3. ASL has no material adverse disciplinary history as on the date of publication of this report.
4. I/We, Preeyam Tolia (MBA & CFA L1) and Suhane Shome (MBA) hereby certify that all of the views expressed in this research report accurately reflect my/our views about the subject issuer(s) or securities. I/We (Research Analyst) also certify that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. I/we or my/our relative or ASL does not have any financial interest in the subject company. Also I/we or my/our relative or ASL or its Associates may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Since associates of ASL are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report. I/we or my/our relative or ASL or its associate does not have any material conflict of interest. I/we have not served as director / officer, employee etc. in the subject company in the last 12-month period. Any holding in stock – No
5. ASL has not received any compensation from the subject company in the past twelve months. ASL has not been engaged in market making activity for the subject company.
6. In the last 12-month period ending on the last day of the month immediately preceding the date of publication of this research report, ASL or any of its associates may have:

Received compensation for investment banking, merchant banking or stock broking services or for any other services from the subject company of this research report and / or; Managed or co-managed public offering of the securities from the subject company of this research report and / or; Received compensation for products or services other than investment banking, merchant banking or stock broking services from the subject company of this research report; ASL or any of its associates have not received compensation or other benefits from the subject company of this research report or any other third-party in connection with this report.

Term & Conditions:

This report has been prepared by ASL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ASL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ASL will not treat recipients as customers by virtue of their receiving this report.

DEFINITION OF RATINGS	
Ratings	Expected absolute returns over 12-18 months
BUY	More than 10%
HOLD	Between 10% and -10%
SELL	Less than -10%
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning valuation and recommendation
UNDER REVIEW	We will revisit our recommendation, valuation and estimates on the stock following recent events
NO STANCE	We do not have any forward looking estimates, valuation or recommendation for the stock

Disclaimer:

Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to the recipient's specific circumstances. The securities and strategies discussed and opinions expressed, if any, in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

This report may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this report should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this report (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. Certain transactions, including those involving futures, options and other derivatives as well as non-investment grade securities involve substantial risk and are not suitable for all investors. ASL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc. Past performance is not necessarily a guide to future performance. Investors are advised necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ASL and its affiliated companies, their directors and employees may; (a) from time to time, have long or short position(s) in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities or earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or investment banker, lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting this document.

ASL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that ASL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. ASL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. The Research reports are also available & published on AxisDirect website.

Neither this report nor any copy of it may be taken or transmitted into the United States (to U.S. Persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof. If this report is inadvertently sent or has reached any individual in such country, especially, USA, the same may be ignored and brought to the attention of the sender. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ASL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors.

The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. The Company reserves the right to make modifications and alterations to this document as may be required from time to time without any prior notice. The views expressed are those of the analyst(s) and the Company may or may not subscribe to all the views expressed therein.

Copyright in this document vests with Axis Securities Limited.

Axis Securities Limited, SEBI Single Reg. No.- NSE, BSE & MSEI – INZ000161633, ARN No. 64610, CDSL-IN-DP-CDSL-693-2013, SEBI-Research Analyst Reg. No. INH 000000297, SEBI Portfolio Manager Reg. No. - INP000000654, Main/Dealing off.- Axis Securities Ltd, Unit No.1001, 10th Floor, Level-6, Q2 Building, Aurum, Q Parc, Plot No. 4/1, TTC, Thane – Belapur Road, Ghansoli, Navi Mumbai. – 400 710., Regd. off.- Axis House, 8th Floor, Wadia International Centre, PandurangBudhkar Marg, Worli, Mumbai – 400 025. Compliance Officer: Jatin Sanghani, Email: compliance.officer@axisdirect.in, Tel No: 022-49212706